Floatz logo

FILGRASTIM

Iron Overload

Beni-Suef Universityprotein_peptidePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Iron Overload cohort.

Asset / SponsorPhaseRating
Deferasirox
Kevin H.M. Kuo, MD, MSc, FRCPC
Phase 4BBB
Deferiprone
Chiesi Canada Corp
Phase 4BBB
DESFERRIOXAMINE B
Beni-Suef University
Phase 4BBB
AMLODIPINE
Kevin H.M. Kuo, MD, MSc, FRCPC
Phase 3BB
Hydroxyurea
Beni-Suef University
Phase 2/3B

View all 13 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →